ArticleAmerican journal of translational research2026
GSDME-mediated pyroptosis is essential for the chemotherapeutic effects achieved by combined treatment of temsirolimus and 5-fluorouracil in ovarian carcinoma cells.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe expression of GSDMD and GSDME in ovarian cancerous tissues, adjacent tissues, and cancer cell lines remain poorly characterized. The contribution of pyroptosis to the synergistic therapeutic effects of PI3K-AKT-mTOR inhibitors and cell cycle inhibitors in ovarian carcinoma is unknown.
methodGSDME and GSDMD expression were quantified in ovarian cancer tissues, adjacent tissues, and cancer cell lines. The cytotoxic effects of temsirolimus (an PI3K-AKT-mTOR inhibitor) and 5-fluorouracil (5-FU, a cell cycle inhibitor) were assessed.
resultsBoth GSDMD and GSDME were detected in ovarian cancer tissues and adjacent tissues. However, the N-terminals of GSDME and GSDMD were only expressed in cancerous tissues, with the GSDME-N terminal being particularly prominent. Similarly, in ovarian cancer cell lines, only GSDME-N terminal was increased when treated by temsirolimus and 5-FU, together with significantly suppressed cell proliferation. Synergistic treatment with temsirolimus and 5-FU further reduced cancer cell viability and enhanced pyroptosis by upregulating GSDME-N terminal expression. RNA interference confirmed that GSDME-mediated pyroptosis is essential for the cytotoxic effects of monotherapy and combination chemotherapy. 5-FU fails to induce complete conversion of pyroptosis to ferroptosis when combined with temsirolimus, even at extremely high concentrations. The drug combination also promoted apoptosis and ferroptosis, which were significantly attenuated by N-acetyl-L-cysteine (NAC).
conclusionGSDME is the principal executor of spontaneous pyroptosis in ovarian cancer tissues. In chemotherapy employing cell cycle-targeting agents or PI3K-AKT-mTOR pathway inhibitors (alone or in combination) is beneficial, and pyroptosis is an indispensable cell death mechanism. Reactive oxygen species act as a nodal regulator orchestrating pyroptosis, apoptosis, and ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.